Today - Tuesday, January 31, the Library Database A-Z list and E-Journal A-Z List
will not be reliable for several hours and maybe a longer time period.
Please use LYMAN : the online catalog for access to
most database and journal titles that you are looking for.
IT is working hard to resolve the server issues.
Please call the Reference Desk 679-2942
or call the Serials Dept -- 679-2432 or 679-4287
for help in identifying any electronic resource access issues that you might be experiencing.
LYMAN online catalog link :
http://lymannet.uchc.edu/
Library Home Page Link :
http://library.uchc.edu/
Tuesday, January 31, 2006
Friday, January 27, 2006
Library Database A-Z list and E-Journal A-Z List will not be reliable for several hours and maybe longer
Today - Friday January 27, the Library Database A-Z list and E-Journal A-Z List
will not be reliable for several hours and maybe a longer time period.
Please use LYMAN : the online catalog for access to
most database and journal titles that you are looking for.
LYMAN online catalog link :
http://lymannet.uchc.edu/
Library Home Page Link :
http://library.uchc.edu/
will not be reliable for several hours and maybe a longer time period.
Please use LYMAN : the online catalog for access to
most database and journal titles that you are looking for.
LYMAN online catalog link :
http://lymannet.uchc.edu/
Library Home Page Link :
http://library.uchc.edu/
Wednesday, January 25, 2006
R2Library has expanded. Check it out.
The R2Library of online textbooks has been expanded. Check it out.
Create a personal login in MyR2 to save bookmarks, save searches.
Searches may be limited to search only purchased titles as well.
Click on the tab marked : Reserve shelf to view online - the list of purchased titles.
http://www.r2library.com/
The following titles have been added :
Anesthetic and obstetric management of high-risk pregnancy
Basic and clinical neurocardiology
Basic science of oncology
Current care of women : diagnosis & treatment
Current Consult : Cardiology
Degowins diagnostic examination
Essential pediatric allergy, asthma and immunology
Essentials of clinical geriatrics
Functional neuroanatomy
Grant application writers handbook
Guide to community preventive services : what works to promote health?
Infertility
Medical complications in pregnancy
Medical interview
Pediatric toxicology
Principles and practice of pain medicine
Principles of critical care
Principles of neuro-oncology
Create a personal login in MyR2 to save bookmarks, save searches.
Searches may be limited to search only purchased titles as well.
Click on the tab marked : Reserve shelf to view online - the list of purchased titles.
http://www.r2library.com/
The following titles have been added :
Anesthetic and obstetric management of high-risk pregnancy
Basic and clinical neurocardiology
Basic science of oncology
Current care of women : diagnosis & treatment
Current Consult : Cardiology
Degowins diagnostic examination
Essential pediatric allergy, asthma and immunology
Essentials of clinical geriatrics
Functional neuroanatomy
Grant application writers handbook
Guide to community preventive services : what works to promote health?
Infertility
Medical complications in pregnancy
Medical interview
Pediatric toxicology
Principles and practice of pain medicine
Principles of critical care
Principles of neuro-oncology
Tuesday, January 24, 2006
Science of Aging Knowledge Environment, SAGE KE
We regret to announce that our e-resource, the Science of Aging Knowledge Environment, SAGE KE (ISSN # 1539-6150),
will discontinue publication after June 30, 2006.
http://sageke.sciencemag.org/index.dtl
Although SAGE KE is a scientific resource of the highest merit with a growing following,
its subscription support did not keep pace with the costs of maintaining the quality and the frequency of ongoing publication.
In contrast, the subscription base for the Signal Transduction Knowledge Environment, STKE,
is sustaining the site and STKE will continue to publish new content each week.
All of the archival content of the SAGE KE, from its inception in October 2001 through the last issue in June 2006,
will become fully accessible for customers with active Science Online subscriptions.
will discontinue publication after June 30, 2006.
http://sageke.sciencemag.org/index.dtl
Although SAGE KE is a scientific resource of the highest merit with a growing following,
its subscription support did not keep pace with the costs of maintaining the quality and the frequency of ongoing publication.
In contrast, the subscription base for the Signal Transduction Knowledge Environment, STKE,
is sustaining the site and STKE will continue to publish new content each week.
All of the archival content of the SAGE KE, from its inception in October 2001 through the last issue in June 2006,
will become fully accessible for customers with active Science Online subscriptions.
Tuesday, January 17, 2006
MUTATION THAT PROTECTS AGAINST HIV INFECTION MAY RAISE RISK OF WEST NILE VIRUS ILLNESS
http://www.nih.gov/news/pr/jan2006/niaid-17.htm
-----Original Message-----
From: NIH news releases and news items [mailto:NIHPRESS@LIST.NIH.GOV]On
Behalf Of NIH OLIB (NIH/OD)
Sent: Tuesday, January 17, 2006 11:25 AM
To: NIHPRESS@LIST.NIH.GOV
Subject: [NIHPRESS] MUTATION THAT PROTECTS AGAINST HIV INFECTION MAY
RAISE RISK OF WEST NILE VIRUS ILLNESS
U.S. Department of Health and Human Services
NATIONAL INSTITUTES OF HEALTH
NIH News
National Institute of Allergy and Infectious Diseases (NIAID)
http://www.niaid.nih.gov/
EMBARGOED FOR RELEASE: Tuesday, January 17, 2006, 9:00 a.m. ET
CONTACT: Anne A. Oplinger, 301-402-1663, aoplinger@niaid.nih.gov
MUTATION THAT PROTECTS AGAINST HIV INFECTION MAY RAISE RISK OF WEST NILE VIRUS ILLNESS
People who lack a cell surface protein called CCR5 are highly resistant to infection by HIV but may be at increased risk of developing West Nile virus (WNV) illness when exposed to the mosquito-borne virus, report researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The study, by Philip M. Murphy, M.D., and colleagues, appears online today in "The Journal of Experimental Medicine". The findings may have cautionary implications for physicians who are treating HIV-positive individuals with experimental CCR5-blocking drugs, say the scientists.
"This is the first genetic risk factor to be identified for West Nile virus infection," says NIH Director Elias A. Zerhouni, M.D. "While infection does not always lead to illness, the virus can sometimes cause serious problems and, according to the Centers for Disease Control and Prevention, there were 102 deaths in the United States from West Nile virus infection in 2005."
"A decade ago, a number of research groups, including Dr. Murphy's, determined that CCR5 is the primary co-receptor used by HIV to infect cells," says NIAID Director Anthony S. Fauci, M.D. "Their work laid the foundation for the development of CCR5-blocking drugs, which are designed to slow the spread of HIV from cell to cell."
Most people inherit two normal copies (one from each parent) of the gene that codes for CCR5 protein. About 1 percent of North American whites, however, have a mutation in both copies (are homozygous) and thus do not produce any CCR5. These individuals have the good fortune of being highly resistant to HIV infection and otherwise seemed to suffer no ill effects from the absence of this receptor protein, scientists noted. But the new research by Dr. Murphy's team suggests that lacking CCR5 may not be an unalloyed good after all.
In 2005 Dr. Murphy and his coworkers developed a mouse model to clarify the roles of various immune system cells in responding to WNV infection. They discovered that while most wild-type mice survived WNV infection, mice genetically engineered to lack CCR5 receptors suffered rapid and uniformly fatal infection by the virus. Further investigation showed that CCR5 promoted the movement of several classes of immune system cells into the brain and central nervous system, which appeared to protect normal mice from the encephalitis (brain inflammation) characteristic of serious WNV infection.
"We wanted to know if humans lacking CCR5 might be at greater risk of the more serious complications of WNV infection," says Dr. Murphy. The researchers examined human blood and cerebrospinal fluid samples from 417 laboratory-confirmed cases of WNV infection that occurred in Arizona and Colorado in 2003 and 2004. Of these, 395 were suitable for genetic testing for the presence or absence of the HIV-protective mutation.
Dr. Murphy and his colleagues determined that 4.5 percent of 247 WNV-positive samples from Arizona were from patients who had two copies of the CCR5 mutation. In contrast, a control group of 145 WNV-negative blood samples showed 0.7 percent were from people who had two copies of the CCR5 mutation -- a number in line with the expected 0.8 to 1 percent range believed to be present in all North American whites. Next, the researchers analyzed the WNV-positive samples from Colorado and determined that 4.1 percent of the entire set of 148 samples came from individuals homozygous for the CCR5 mutation. Among those Coloradans who provided WNV-positive samples and who self-reported their race as white, the percentage of homozygous individuals was 8.3.
The absence of normal CCR5 genes is a strong genetic risk factor for developing symptomatic cases of WNV infection, the researchers conclude. "The findings may have important clinical implications for physicians who treat people with HIV," notes Dr. Murphy. For example, he says, it may be prudent for HIV-positive individuals who are taking experimental CCR5-blockers to strictly limit mosquito exposure.
News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.
NIAID is a component of the National Institutes of Health, an agency of the U.S. Department of Health and Human Services. NIAID supports basic and applied research to prevent, diagnose and treat infectious diseases such as HIV/AIDS and other sexually transmitted infections, influenza, tuberculosis, malaria and illness from potential agents of bioterrorism. NIAID also supports research on transplantation and immune-related illnesses, including autoimmune disorders, asthma and allergies.
The National Institutes of Health (NIH) -- "The Nation's Medical Research Agency" -- includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary Federal agency for conducting and supporting basic, clinical, and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.
##
------------------------------------------------------------
References: WG Glass "et al". Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. "The Journal of Experimental Medicine" 202:1087-98 (2005). DOI:10.1084/jem.20042530.
WG Glass "et al". CCR5 deficiency increases risk of symptomatic West Nile virus infection. "The Journal of Experimental Medicine". (Published online Jan. 17, 2006) DOI: 10.1084/jem.20051970.
------------------------------------------------------------
This NIH News Release is available online at:
http://www.nih.gov/news/pr/jan2006/niaid-17.htm.
To subscribe (or unsubscribe) from this list, go to
http://list.nih.gov/cgi-bin/wa?SUBED1=nihpress&A=1.
-----Original Message-----
From: NIH news releases and news items [mailto:NIHPRESS@LIST.NIH.GOV]On
Behalf Of NIH OLIB (NIH/OD)
Sent: Tuesday, January 17, 2006 11:25 AM
To: NIHPRESS@LIST.NIH.GOV
Subject: [NIHPRESS] MUTATION THAT PROTECTS AGAINST HIV INFECTION MAY
RAISE RISK OF WEST NILE VIRUS ILLNESS
U.S. Department of Health and Human Services
NATIONAL INSTITUTES OF HEALTH
NIH News
National Institute of Allergy and Infectious Diseases (NIAID)
http://www.niaid.nih.gov/
EMBARGOED FOR RELEASE: Tuesday, January 17, 2006, 9:00 a.m. ET
CONTACT: Anne A. Oplinger, 301-402-1663, aoplinger@niaid.nih.gov
MUTATION THAT PROTECTS AGAINST HIV INFECTION MAY RAISE RISK OF WEST NILE VIRUS ILLNESS
People who lack a cell surface protein called CCR5 are highly resistant to infection by HIV but may be at increased risk of developing West Nile virus (WNV) illness when exposed to the mosquito-borne virus, report researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The study, by Philip M. Murphy, M.D., and colleagues, appears online today in "The Journal of Experimental Medicine". The findings may have cautionary implications for physicians who are treating HIV-positive individuals with experimental CCR5-blocking drugs, say the scientists.
"This is the first genetic risk factor to be identified for West Nile virus infection," says NIH Director Elias A. Zerhouni, M.D. "While infection does not always lead to illness, the virus can sometimes cause serious problems and, according to the Centers for Disease Control and Prevention, there were 102 deaths in the United States from West Nile virus infection in 2005."
"A decade ago, a number of research groups, including Dr. Murphy's, determined that CCR5 is the primary co-receptor used by HIV to infect cells," says NIAID Director Anthony S. Fauci, M.D. "Their work laid the foundation for the development of CCR5-blocking drugs, which are designed to slow the spread of HIV from cell to cell."
Most people inherit two normal copies (one from each parent) of the gene that codes for CCR5 protein. About 1 percent of North American whites, however, have a mutation in both copies (are homozygous) and thus do not produce any CCR5. These individuals have the good fortune of being highly resistant to HIV infection and otherwise seemed to suffer no ill effects from the absence of this receptor protein, scientists noted. But the new research by Dr. Murphy's team suggests that lacking CCR5 may not be an unalloyed good after all.
In 2005 Dr. Murphy and his coworkers developed a mouse model to clarify the roles of various immune system cells in responding to WNV infection. They discovered that while most wild-type mice survived WNV infection, mice genetically engineered to lack CCR5 receptors suffered rapid and uniformly fatal infection by the virus. Further investigation showed that CCR5 promoted the movement of several classes of immune system cells into the brain and central nervous system, which appeared to protect normal mice from the encephalitis (brain inflammation) characteristic of serious WNV infection.
"We wanted to know if humans lacking CCR5 might be at greater risk of the more serious complications of WNV infection," says Dr. Murphy. The researchers examined human blood and cerebrospinal fluid samples from 417 laboratory-confirmed cases of WNV infection that occurred in Arizona and Colorado in 2003 and 2004. Of these, 395 were suitable for genetic testing for the presence or absence of the HIV-protective mutation.
Dr. Murphy and his colleagues determined that 4.5 percent of 247 WNV-positive samples from Arizona were from patients who had two copies of the CCR5 mutation. In contrast, a control group of 145 WNV-negative blood samples showed 0.7 percent were from people who had two copies of the CCR5 mutation -- a number in line with the expected 0.8 to 1 percent range believed to be present in all North American whites. Next, the researchers analyzed the WNV-positive samples from Colorado and determined that 4.1 percent of the entire set of 148 samples came from individuals homozygous for the CCR5 mutation. Among those Coloradans who provided WNV-positive samples and who self-reported their race as white, the percentage of homozygous individuals was 8.3.
The absence of normal CCR5 genes is a strong genetic risk factor for developing symptomatic cases of WNV infection, the researchers conclude. "The findings may have important clinical implications for physicians who treat people with HIV," notes Dr. Murphy. For example, he says, it may be prudent for HIV-positive individuals who are taking experimental CCR5-blockers to strictly limit mosquito exposure.
News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.
NIAID is a component of the National Institutes of Health, an agency of the U.S. Department of Health and Human Services. NIAID supports basic and applied research to prevent, diagnose and treat infectious diseases such as HIV/AIDS and other sexually transmitted infections, influenza, tuberculosis, malaria and illness from potential agents of bioterrorism. NIAID also supports research on transplantation and immune-related illnesses, including autoimmune disorders, asthma and allergies.
The National Institutes of Health (NIH) -- "The Nation's Medical Research Agency" -- includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary Federal agency for conducting and supporting basic, clinical, and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.
##
------------------------------------------------------------
References: WG Glass "et al". Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. "The Journal of Experimental Medicine" 202:1087-98 (2005). DOI:10.1084/jem.20042530.
WG Glass "et al". CCR5 deficiency increases risk of symptomatic West Nile virus infection. "The Journal of Experimental Medicine". (Published online Jan. 17, 2006) DOI: 10.1084/jem.20051970.
------------------------------------------------------------
This NIH News Release is available online at:
http://www.nih.gov/news/pr/jan2006/niaid-17.htm.
To subscribe (or unsubscribe) from this list, go to
http://list.nih.gov/cgi-bin/wa?SUBED1=nihpress&A=1.
Tuesday, January 10, 2006
ToxSeek : a meta-search engine from the NLM
ToxSeek (http://toxSeek.nlm.nih.gov) is a meta-search engine that enables simultaneous searching of many different information resources on the World Wide Web. The ToxSeek user interface allows selection of resources from a wide range of authoritative sources in these categories:
TOXNET (NLM): Databases on hazardous chemicals, toxic releases and environmental health from the National Library of Medicine (NLM)
NLM: Additional selected resources from the National Library of Medicine (NLM), including PubMed
NIH: Resources from other institutes of the National Institutes of Health (NIH)
U.S. Government: Toxicology/environmental health information from other United States government agencies
International: Other selected international resources, such as the World Health Organization (WHO)
Resources/Societies: Other topic-specific information resources
ToxSeek uses natural language processing and artificial intelligence to retrieve, integrate, rank, and present search results as coherent and dynamic sets. ToxSeek searches across diverse biomedical and environmental health resources and so provides a way to efficiently locate information resources on topics related to toxicology and environmental health.
In ToxSeek, select an information category (or choose to “view all categories”) and enter a search term/s in the box. Boolean operators should NOT be used as the search is run against sources which handle queries in different ways. The ToxSeek results page returns resources in relevance order; this can be changed via the pull-down box to either alphabetical or source order.
ToxSeek’s results “clustering” feature helps users to more easily identify particular concepts. These “clusters” are created from what is retrieved in the original query, and can be useful in uncovering a specific concept or focus for more in-depth searching.
TOXNET (NLM): Databases on hazardous chemicals, toxic releases and environmental health from the National Library of Medicine (NLM)
NLM: Additional selected resources from the National Library of Medicine (NLM), including PubMed
NIH: Resources from other institutes of the National Institutes of Health (NIH)
U.S. Government: Toxicology/environmental health information from other United States government agencies
International: Other selected international resources, such as the World Health Organization (WHO)
Resources/Societies: Other topic-specific information resources
ToxSeek uses natural language processing and artificial intelligence to retrieve, integrate, rank, and present search results as coherent and dynamic sets. ToxSeek searches across diverse biomedical and environmental health resources and so provides a way to efficiently locate information resources on topics related to toxicology and environmental health.
In ToxSeek, select an information category (or choose to “view all categories”) and enter a search term/s in the box. Boolean operators should NOT be used as the search is run against sources which handle queries in different ways. The ToxSeek results page returns resources in relevance order; this can be changed via the pull-down box to either alphabetical or source order.
ToxSeek’s results “clustering” feature helps users to more easily identify particular concepts. These “clusters” are created from what is retrieved in the original query, and can be useful in uncovering a specific concept or focus for more in-depth searching.
Tuesday, January 03, 2006
2006 Childhood and Adolescent Immunization Schedule Released
Red Book Online -- Announcement
** Red Book Online Special Alert **
2006 Childhood and Adolescent Immunization Schedule Released
http://www.aapredbook.org
The American Academy of Pediatrics (AAP) has issued the recommended 2006
childhood and adolescent immunization schedule for the United States.
The statement represents joint recommendations from the AAP,
the Advisory
Committee on Immunization Practices (ACIP) of the Centers for Disease
Control and Prevention (CDC),
and the American Academy of Family Physicians (AAFP).
The 2006 schedule reflects several changes including the following:
* Hepatitis A vaccine is now recommended for universal administration
to all infants 12 to 23 months of age, with a second dose six months
later.
* A single dose of meningococcal conjugate vaccine, a vaccine to
prevent sepsis and meningitis, is recommended for all 11- to
12-year-olds, for adolescents at high school entry or 15 years of age,
and for college freshmen who will be living in a dormitory.
* A single dose of an adolescent preparation of tetanus and diphtheria
toxoids and acellular pertussis (Tdap) vaccine is recommended for 11-
to 12-year-olds, provided they have not received a tetanus and
diphtheria (Td) booster dose, and for adolescents 13 to 18 years of
age who missed the 11- to 12-year-old Td or Tdap booster dose.
Please see the new schedule, including the 2006 Catch-Up Schedule, on Red
Book Online at http://www.aapredbook.org
Both schedules will be freely accessible to all visitors to the site.
A licensure application has been submitted to the Food and Drug
Administration for a live, oral rotavirus vaccine.
The AAP is considering recommendations for use of this vaccine.
Any applicable updates on the potential licensures and recommendations will be posted on the Red Book
Online table "Status of Licensure and Recommendations for New Vaccines" at
http://www.aapredbook.org/vaccstatus.shtml
* * * * * *
A great resource for your practice or your waiting room, the new AAP
parenting guide, Immunizations & Infectious Diseases: An Informed Parent's
Guide, edited by Margaret C. Fisher, MD, FAAP, is now available via the AAP
Online Bookstore at
http://www.aap.org/bst/showdetl.cfm?&DID=15&Product_ID=4135
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
This message was sent to dobbs@nso.uchc.edu.
Unsubscribe or edit your subscriptions for this service at:
http://aapredbook.aappublications.org/cgi/alerts
Or by mail:
Customer Service * 1454 Page Mill Road * Palo Alto, CA 94304 * U.S.A.
_______________________________________________________________________
Copyright (c) 2006 by the American Academy of Pediatrics.
** Red Book Online Special Alert **
2006 Childhood and Adolescent Immunization Schedule Released
http://www.aapredbook.org
The American Academy of Pediatrics (AAP) has issued the recommended 2006
childhood and adolescent immunization schedule for the United States.
The statement represents joint recommendations from the AAP,
the Advisory
Committee on Immunization Practices (ACIP) of the Centers for Disease
Control and Prevention (CDC),
and the American Academy of Family Physicians (AAFP).
The 2006 schedule reflects several changes including the following:
* Hepatitis A vaccine is now recommended for universal administration
to all infants 12 to 23 months of age, with a second dose six months
later.
* A single dose of meningococcal conjugate vaccine, a vaccine to
prevent sepsis and meningitis, is recommended for all 11- to
12-year-olds, for adolescents at high school entry or 15 years of age,
and for college freshmen who will be living in a dormitory.
* A single dose of an adolescent preparation of tetanus and diphtheria
toxoids and acellular pertussis (Tdap) vaccine is recommended for 11-
to 12-year-olds, provided they have not received a tetanus and
diphtheria (Td) booster dose, and for adolescents 13 to 18 years of
age who missed the 11- to 12-year-old Td or Tdap booster dose.
Please see the new schedule, including the 2006 Catch-Up Schedule, on Red
Book Online at http://www.aapredbook.org
Both schedules will be freely accessible to all visitors to the site.
A licensure application has been submitted to the Food and Drug
Administration for a live, oral rotavirus vaccine.
The AAP is considering recommendations for use of this vaccine.
Any applicable updates on the potential licensures and recommendations will be posted on the Red Book
Online table "Status of Licensure and Recommendations for New Vaccines" at
http://www.aapredbook.org/vaccstatus.shtml
* * * * * *
A great resource for your practice or your waiting room, the new AAP
parenting guide, Immunizations & Infectious Diseases: An Informed Parent's
Guide, edited by Margaret C. Fisher, MD, FAAP, is now available via the AAP
Online Bookstore at
http://www.aap.org/bst/showdetl.cfm?&DID=15&Product_ID=4135
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
This message was sent to dobbs@nso.uchc.edu.
Unsubscribe or edit your subscriptions for this service at:
http://aapredbook.aappublications.org/cgi/alerts
Or by mail:
Customer Service * 1454 Page Mill Road * Palo Alto, CA 94304 * U.S.A.
_______________________________________________________________________
Copyright (c) 2006 by the American Academy of Pediatrics.
Subscribe to:
Posts (Atom)
Posts
